The MassBio Annual Meeting focuses on the most critical challenges facing the Massachusetts life sciences industry. The meeting program is designed by a steering committee of industry leaders and the agenda encompasses keynote presentations, panel discussions, interactive working sessions and extensive networking opportunities.
The MassBio Annual Meeting also includes the Innovative Leadership Award Luncheon, which honors an industry leader for his or her contribution to moving the life sciences industry forward.
Dr. Coles is a founding investor and the chairman and chief executive officer of Yumanity Therapeutics, a Cambridge, MA-based biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding such as Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis (ALS).
Dr. Coles also serves as chairman and chief executive officer of TRATE Enterprises, LLC, a privately held company.
Previously, Dr. Coles was chairman and chief executive officer of Onyx Pharmaceuticals, Inc., which was acquired by Amgen in late 2013. Under his leadership, Onyx introduced two new innovative cancer medicines to patients and established the company’s international presence outside of the U.S. Prior to joining Onyx in 2008, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., and earlier, held a number of executive positions at Bristol-Myers Squibb Company. Additionally, from 1992 until 1996, Dr. Coles held a number of positions of increasing responsibility at Merck & Co., Inc.
Educated at Johns Hopkins University, he earned an M.D. from Duke University and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.
Dr. Coles currently serves on the board of CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases He also serves as a member of the board of directors of McKesson Corporation (NYSE: MCK), is vice chair of the board of trustees for Johns Hopkins University and is a member of the board of trustees for Johns Hopkins Medicine. In March 2015, Dr. Coles was named to the National Institutes of Health (NIH) working group tasked with charting the course for President Obama’s Precision Medicine Initiative, now part of the PMI Cohort Program Advisory Panel. Dr. Coles also serves as a member of the council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the board of trustees for The Metropolitan Museum of Art in New York City; and a member of the Council on Foreign Relations, an independent, nonpartisan membership organization, think tank, and publisher.
Since taking office in January, 2015, Governor Charlie Baker has been making Massachusetts a great place to live, work, start a business and raise a family while delivering a customer service oriented state government that is as thrifty, creative and hard working as the people of Massachusetts.Governor Baker called on an expert, bipartisan team of Republicans, Democrats and Independents to lead his cabinet.
Together, they are fulfilling his commitment to building stronger and safer communities for our children and families; keeping our roads and bridges safe and reliable; protecting our natural resources; and ensuring our schools and students are successful and safe.
From resolve in the face of unprecedented snow and freezing temperatures, to working to fix the MBTA,the Department of Children and Families, the Health Connector and Registry of Motor Vehicles, to balancing budgets despite billions in deficits all without raising taxes – the Baker Polito Administration is making state government truly work for the people of Massachusetts.
Send this to a friend